115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Role of PD-1hiFoxp3-CD4+tumor-infiltrating lymphocytes in the immunotherapy response
    Meeting Abstract

    Zappasodi, R.; Mangarin, L. M.; Martis, S.; Orlando, A.; Schad, S.; Wolchok, J. D.; Greenbaum, B.; Merghoub, T.
    Cancer Science (2024)

    Fulltext@MSK | Save
  • Evaluation of teclistamab in BCMA-directed therapy exposed versus naive in relapsed/refractory multiple myeloma
    Meeting Abstract

    Snyder, J.; Graf, K.; Davis, J. A.; McKenna, M.; Tiger, Y. K.; Laharwal, M. M.; Mewawalla, P.; Alkharabsheh, O.; Hashmi, H.; Shaikh, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • RNA methylation and control of RNA and cellular fates
    Meeting Abstract

    Kharas, M. G.
    Cancer Science (2024)

    Fulltext@MSK | Save
  • A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i)
    Meeting Abstract

    Mascarenhas, J. O.; Borate, U.; Bose, P.; Byrd, J. C.; Garcia, J. S.; Grunwald, M. R.; Hobbs, G. S.; Hoffman, R.; Kuykendall, A. T.; Mesa, R. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib
    Meeting Abstract

    Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A real-world analysis of the safety and efficacy of teclistamab for patients with relapsed/refractory multiple myeloma and baseline renal impairment
    Meeting Abstract

    Habib, A.; Khan, A. M.; Laharwal, M. M.; Mewawalla, P.; McKenna, M.; Tiger, Y. K.; Shaikh, H.; Strouse, C.; Green, K. M.; Davis, J. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world efficacy outcomes of ciltacabtagene autoleucel in relapsed refractory multiple myeloma: A with the CARTITUDE-1 trial
    Meeting Abstract

    Kamboj, I.; Chang, D. R. Y.; Habib, A.; Vegel, A.; Struble, E.; Shaikh, H.; Strouse, C.; Davis, J. A.; Rashid, A.; Graf, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Practice patterns inform patient-centered approaches for the integration of BTK inhibitors in frontline mantle cell lymphoma
    Meeting Abstract

    Graham, T.; Ackbarali, T.; Kumar, A.; Matasar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • The burden of hematologic malignancies in Southeast Asia from 1990 to 2021: Estimates from the Global Burden of Disease Study
    Meeting Abstract

    Ho, F. D. V.; Dee, E. C.; Feliciano, E. J. G.; Jain, U.; Sekolar, A.; Jain, B.; Columbres, R. C.; Swami, N.; Wu, J. F.
    Blood (2024)

    Fulltext@MSK | Save
  • Representation of older adults in FDA and EMA registrational trials for diffuse large B cell lymphoma (DLBCL)
    Meeting Abstract

    Juthani, R.; Pugh, K.; Neuendorff, N.; Torka, P.
    Blood (2024)

    Fulltext@MSK | Save